Novo Nordisk's tablet won 3.6 million U.S. scripts at about $174 each — and 2026 revenue is still capped at +2%

• U.S. prescriptions reached about 3.6 million in the quarter and more than 8 million since launch, with over 30% of weekly scripts at the 9 mg and 25 mg doses.
• The Medicare bridge went live on 1 July 2026 covering the majority of Part D beneficiaries, and Novo describes early uptake as encouraging.
• Novo also disclosed roughly 55,000 active subscription customers at the end of the quarter.
• The tablet took 27% of U.S. Wegovy revenue in the quarter, which is why U.S. obesity sales grew 20% at constant exchange rates on volume while total U.S. Operations grew only 1%.

• Cash tier: $149 a month for the 1.5 mg and 4 mg doses and up to $299 for higher doses, sold direct to self-pay patients.
• Medicare bridge: $245 net price per month of supply from 1 July 2026 to 31 December 2027, with a $50 beneficiary copay, and manufacturers repay the difference between list price and $245 while Part D sponsors carry no financial risk on those scripts.
• From 1 January 2027 the U.S. list price of Wegovy, Ozempic and Rybelsus falls to $675 a month for all doses — up to a 50% cut on Wegovy.
• Novo said gross-to-net adjustments were neutral to growth in the third quarter, so the reset is list-price architecture rather than deeper rebates.

• Novo Nordisk brought three Catalent fill-finish sites in-house for $11bn in 2024 and cut 2026 capital expenditure to about DKK 50bn, so device and vial capacity is no longer what constrains the tablet.
• Every converted patient multiplies semaglutide tonnage roughly 72-fold before purification losses, which makes the oral ramp an API and purification problem rather than a pen problem.
• McKesson books GLP-1 distribution revenue of $15bn a quarter on a 3.5% gross margin, so the channel is paid on throughput rather than on price.
• Semaglutide's compound patent in China expired on 20 March 2026 after the Supreme People's Court upheld it in December 2025, opening the lowest-price volume market to generic product and API.

“We delivered a stronger-than-expected third quarter and are raising our full-year outlook for adjusted sales and adjusted operating profit. We are particularly pleased to see both US Operations and International Operations deliver sales growth this quarter. Growth was led by our obesity portfolio, with continued uptake of Wegovy pill in the US and encouraging early launches internationally.”

• Volume is no longer the scarce resource: 3.6 million U.S. tablet scripts in one quarter at about $174 each is a larger pool of patients than the old net price can serve profitably.
• Free cash flow guidance rose DKK 15bn at the midpoint while sales went nowhere, because the channels generating the volume — cash-pay and the manufacturer-funded bridge — carry no rebate stack.
• Lilly's oral pill is still sub-scale: Foundayo booked $184 million in the quarter against $810 million for Novo's tablet, and Lilly launched three months later.
• The positioning conclusion: own the distributors and dispensing economics for volume, and own the manufacturers for cash conversion rather than for growth.

• Near term: the December quarter is guided to roughly 6% below the year-ago quarter at constant exchange rates, so the next print reads as a price event even if scripts keep compounding.
• Near term: a flat prescription curve in the fourth quarter would turn the tablet's 68% sequential growth into a pull-forward story, and management has already flagged the flattening.
• The bridge's expiry on 31 December 2027 is the single largest binary in U.S. GLP-1 pricing, since renewal at a higher net price would lift manufacturer revenue per patient without a single extra script.
• Long term: CagriSema's U.S. launch in early 2027 is the first test of whether a new molecule can outrun the price reset on the injectable.
• Structural risk: China. The semaglutide compound patent expired on 20 March 2026 and Novo already cut Chinese list prices in late 2025, so international realised prices fall as volume rises.